

MOLECULAR IMAGING IN DRUG DISCOVERY AND DEVELOPMENT

Markus Rudin* and Ralph Weissleder[‡]

Imaging sciences have grown exponentially during the past three decades, and many techniques, such as magnetic resonance imaging, nuclear tomographic imaging and X-ray computed tomography, have become indispensable in clinical use. Advances in imaging technologies and imaging probes for humans and for small animals are now extending the applications of imaging further into drug discovery and development, and have the potential to considerably accelerate the process. This review summarizes some of the recent developments in conventional and molecular imaging, and highlights their impact on drug discovery.

MAGNETIC RESONANCE IMAGING (MRI). A powerful diagnostic imaging method that uses radiowaves in the presence of a magnetic field to extract information from certain atomic nuclei (most commonly hydrogen). It is primarily used for producing anatomical images, but also gives information on the physico-chemical state of tissues, flow, diffusion, motion and, more recently, molecular targets.

*Novartis Institute for Biomedical Research, CH-4002 Basel, Switzerland.
[‡]Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Boston, Charlestown, Massachusetts 02129, USA.
 Correspondence to R.W. e-mail: weissleder@helix.mgh.harvard.edu
 doi:10.1038/nrd1007

Imagine seeing a specific molecular target in a live animal, following a drug's distribution in the same animal and quantitating the drug's direct effect on the target, all in a matter of minutes. Although this prospect might have seemed utopian a few years ago, enabling technologies, such as novel imaging modalities and molecular probes, are being developed at a rapid pace and should allow these questions to be addressed routinely in the not-too-distant future. The widespread availability of mouse imaging systems is not as far off as many researchers might think. These systems (TABLE 1) are generally cheaper than their clinical counterparts and can be housed in basic science laboratories (see REF. 1 for a review). Given the increasingly common use of mouse models of disease to validate potential drug targets, to assess therapeutic efficacy and to identify and validate biomarkers of drug efficacy and/or safety, the ability to image mouse models non-invasively would have far-reaching applications in drug discovery and development.

Historically, *in vivo* imaging methods have largely relied on imaging gross anatomy, and diseases or treatment effects were mostly detected as structural abnormalities (these methods occasionally being referred to as structural or conventional imaging). With higher spatial resolutions and the advent of imaging agents, it became possible to image at the mesoscale and therefore derive physiological parameters in live subjects (this is often called functional imaging). More recently,

it has become possible to image specific molecules and targets, a field that is often referred to as molecular imaging. Indeed, molecular imaging can be used to either image the administered drug directly (for example, following its distribution and target binding) or the target itself (for example, receptor expression and modulation of downstream targets). For the newer molecular imaging tools to be useful, there are two prerequisites: first, they must have the high sensitivity that is required to monitor interactions at a molecular level and also have sufficiently high spatial resolution to image mouse models of human disease; and second, more target-specific molecular probes must become available. The goal of this paper is to briefly review the available imaging modalities, highlight some uses of anatomical and functional imaging and then focus on exciting advances in molecular imaging (FIG. 1) and how they will affect drug discovery and development. For more in-depth reading on specific imaging modalities and diseases, the reader is referred to several recent review articles^{1–7}.

Imaging modalities

Imaging technologies exploit the interaction of various forms of energy with tissues to non-invasively visualize the body. Some technologies, such as MAGNETIC RESONANCE IMAGING (MRI) and X-RAY COMPUTED TOMOGRAPHY (CT), rely solely on energy–tissue interactions, whereas others, such as POSITRON EMISSION TOMOGRAPHY (PET), require the

Table 1 | Overview of high-resolution, small-animal imaging systems

Technique	Resolution	Depth	Time	Imaging agents	Target*	Cost*	Primary small-animal use	Clinical use
MR	10–100 µm	No limit	Minutes–hours	Gadolinium, dysprosium, iron oxide particles	A, P, M	\$\$\$	Versatile imaging modality with high soft-tissue contrast	Yes
CT	50 µm	No limit	Minutes	Iodine	A, P	\$\$	Lung and bone imaging	Yes
Ultrasound	50 µm	Millimetres	Minutes	Microbubbles	A, P	\$\$	Vascular and interventional imaging	Yes
PET	1–2 mm	No limit	Minutes	¹⁸ F, ¹¹ C, ¹⁵ O	P, M	\$\$\$	Versatile imaging modality with many different tracers	Yes
SPECT	1–2 mm	No limit	Minutes	^{99m} Tc, ¹¹¹ In chelates	P, M	\$\$	Commonly used to image labelled antibodies, peptides and so on	Yes
FRI	2–3 mm	<1 cm	Seconds–minutes	Photoproteins (GFP), NIR fluorochromes	P, M	\$	Rapid screening of molecular events in surface-based tumours	Development
FMT	1 mm	<10 cm	Seconds–minutes	NIR fluorochromes	P, M	\$\$	Quantitative imaging of targeted or ‘smart’ fluorochrome reporters in deep tumours	Development
BLI	Several millimetres	Centimetres	Minutes	Luciferins	M	\$\$	Gene expression, cell and bacterial tracking	No
Intravital microscopy (confocal, multiphoton)	1 µm	<400 µm	Seconds–minutes	Photoproteins (GFP), Fluorochromes	P, M	\$\$\$	All of the above at higher resolutions but at limited depths and coverage	Limited development (skin)

*Primary area that a given imaging modality interrogates: A, anatomical; M, molecular P, physiological. *Cost of system: \$ <100,000; \$\$ 100–300,000; \$\$\$: >300,000. BLI, bioluminescence imaging; CT, X-ray computed tomography; FMT, fluorescence-mediated molecular tomography; FRI, fluorescence reflectance imaging; GFP, green fluorescent protein; NIR; near-infrared; MR, magnetic resonance; PET, positron emission tomography; SPECT, single-photon emission computed tomography.

administration of imaging agents or reporter probes (which can be targeted to specific cells or receptors; see below).

The choice of imaging modality in drug development depends primarily on the specific question to be addressed and different imaging techniques are, in general, complementary rather than competitive. The versatility of MRI has made it a widely used tool in pharmaceutical research. Owing to its excellent soft-tissue contrast properties, MRI allows for the sensitive detection of soft-tissue pathologies and, in addition, yields valuable physiological information. Today, MRI has evolved to be the imaging modality of choice for studying diseases of the central nervous system, such as stroke, neurodegenerative disorders and multiple sclerosis, and provides qualitative diagnostic and quantitative morphometric information, as well as functional/physiological readouts (FIG. 2). The technique is also widely used to diagnose and stage visceral pathologies (for example, neoplastic structures and cardiovascular diseases) or musculoskeletal diseases (for example, rheumatoid arthritis). CT is the classical anatomical imaging modality and is particularly suited for the study of skeletal structures and of the lung. Nuclear imaging techniques such as PET offer the sensitivity required to monitor drug distribution, pharmacokinetics and pharmacodynamics, and for imaging specific molecular end points. Depending on the ligands and radionuclides used, a myriad of molecular end points can potentially be visualized. Newer optical imaging techniques, such as

fluorescence and bioluminescence imaging, are of particular value for mapping specific molecular events in mice and for tracking cells. They are also cheap, fast and do not require radionuclides. Several other imaging technologies (for example, magnetic resonance spectroscopy, electron magnetic resonance and optical spectroscopy) are under development; however, these are less well established for drug development.

Many of these non-invasive technologies were originally developed for human use, but have recently been scaled down to allow the high-resolution imaging of mice. This is highly relevant, because as genomics provides us with better animal models of disease, imaging readouts can be used to evaluate novel therapeutics. In addition, some of the imaging modalities fulfil the bench-to-bedside model, that is, they can be applied to mice, other rodents and primates and can ultimately be used in clinical trials. From the perspective of drug development, such tools will be highly valuable. In the following sections, we consider the integration of non-invasive imaging methods into modern drug discovery and development (FIG. 1).

Structural and functional imaging
Characterizing disease models and evaluating efficacy. High-resolution structural and functional imaging has become increasingly important in drug development, both experimentally and clinically. Its main advantages over other biomarkers (for example, tissue sampling, excision and fluid analysis) are the direct visualization

X-RAY COMPUTED TOMOGRAPHY (CT). As generated X-rays pass through different types of tissue, they are deflected or absorbed to different degrees. CT uses X-rays to obtain three-dimensional images by rotating an X-ray source around the subject and measuring the intensity of transmitted X-rays from different angles.

POSITRON EMISSION TOMOGRAPHY (PET). A tomographic imaging technique that detects nuclides as they decay by positron emission.

of disease processes, the ability to quantitate changes over time and the non-invasive nature of the tests. As an example, FIG. 2 shows how MR can be used to image the development of pathology in a rodent model of human embolic stroke. MR techniques allow the precise localization of the site of vascular occlusion⁸, the quantification of the ensuing perfusion⁹ and the oxygenation deficits¹⁰ leading to energy failure, membrane breakdown and cytotoxic oedema¹¹. Later steps in the pathophysiological cascade include the breakdown of the blood–brain barrier, the formation of vasogenic oedema¹² and the infiltration of inflammatory cells, all of which are detectable by MRI¹³. The efficacy of cytoprotective therapy has been commonly assessed using structural readouts, that is, using estimates of infarct volumes coupled with the assumption that structural damage is a surrogate for clinical outcome. More recent data, however, indicate that structural integrity (that is, normal appearance in anatomical images) is a necessary but not sufficient criterion for functional integrity as revealed by functional MRI (fMRI) studies of brain function¹⁴. Both anatomical and functional read-outs have therefore become established in research to determine the efficacy of newer thrombolytic and cytoprotective therapies^{3,12}. For clinical applications, however, some of these surrogate markers of drug development have not yet been accepted by the US FDA. Similar structural and functional imaging approaches have been used to determine the efficacy of anti-angiogenic therapies^{15–19}, anti-inflammatory treatments^{20,21}, apoptosis-inducing agents^{22–24} and many other areas of drug action.

Labelling the drug

Imaging biodistribution and pharmacokinetics. Although the biodistribution and pharmacokinetics of new agents in rodents are still commonly measured by blood and tissue sampling or autoradiography, nuclear imaging techniques have gained in importance⁷. Nuclear techniques — in particular, quantitative PET imaging — can now be carried out in small rodents^{25–28} and are routinely used in canine and primate models, as well as being used clinically. A particularly exciting aspect of PET is the fact that many drugs can be labelled with ¹¹C or with ¹⁸F (REFS 7,29–34), which

means that labelling only minimally affects, if at all, the chemical/physicochemical properties of the compound, allowing the monitoring of the drug biodistribution. As an example, a study showing the distribution of fluconazole, a fluorine-containing anti-fungal agent, is shown in FIG. 3 (REF. 35). PET imaging was used to obtain detailed quantitative information on fluconazole kinetics and dynamics in various tissues, including the human brain. Another approach frequently used in PET imaging is to analyse the inhibition of specific binding of a well-characterized PET radioligand by an unlabelled drug.

Labelling the target

Imaging target distribution and function. Advances in genomic, proteomic and chemical sciences have accelerated the development of ever-more-precise therapeutics aimed at specific molecular targets associated with disease. Examples of such therapies include inhibitors of specific kinases (for example, Glivec/Gleevec, which targets the BCR–ABL receptor tyrosine kinase³⁶), receptors¹⁵ or proteinases³⁷. Ideally, we would like to monitor these directed therapies by visualizing the intended drug target and then image the functional consequences of drug–target interactions in live animals and, ultimately, in patients. Specifically, we would like to know whether a putative drug reaches the target, whether it affects target expression and/or function (up- or down-regulation, activation or inactivation) and, ultimately, whether the drug has a disease-modifying effect. Such information can potentially be provided by molecular imaging techniques¹. The central challenge for molecular imaging is to develop specific reporter probes and amplification strategies to differentiate target information from non-specific background noise so as to be able to cope with low (sub-nanomolar) target concentrations.

The design of molecular reporter probes is variable, but typically involves either ‘targeted agents’ or ‘activatable agents’¹. Targeted agents are essentially small molecules, peptides, metabolites, aptamers, antibodies or other molecules labelled with a reporter moiety that can be detected by a given imaging modality (for example, ¹¹C- and ¹⁸F-labelled PET ligands^{7,30,33}, ¹¹¹In- or ^{99m}Tc-labelled ligands³⁸, fluorochrome-labelled ligands^{39–41} and magnetic ligands^{42–44}). *In vivo*




Figure 1 | Imaging applications in the drug discovery and development process.

visualization of a target requires specific enrichment of the reporter probe at the target site, that is, we have to wait until the non-bound fraction of the reporter probe is eliminated to minimize the background signal. Many types of targeted imaging agent have been developed for different imaging techniques (BOX 1).

During the past several years, there has been an increasing interest in PET imaging as a tool in central nervous system drug discovery and development^{30,45–53}. This has been primarily due to a growing list of

neuroreceptor-specific PET tracers, improvements in PET camera resolution, the availability of small-animal PET cameras²⁵ and improved communication between academia and drug companies. A significant number of small-molecule receptor ligands have been labelled with ¹¹C and ¹⁸F, and some of these ligands readily cross the blood–brain barrier and bind to their intended targets. In particular, the dopamine and SEROTONIN (5-HT) RECEPTOR SYSTEMS have been investigated^{32,50,54}. Using such specific ligands, PET studies have provided information on the




Figure 2 | Structural and functional imaging. Conventional structural and functional imaging has an increasingly important role in drug development. Using embolic stroke and stroke treatment, this figure summarizes the available imaging read-outs and their role in different therapeutic regimens and timing. Initially, angiographic techniques can visualize the occlusion, while other magnetic resonance imaging techniques allow the visualization of perfusion and oxygenation deficits. At later time points, diffusion and T_2 imaging can be used as surrogates for membrane failure and tissue necrosis (vasogenic oedema). Using imaging agents, cellular infiltration and repair processes can be visualized at later points. Brain function is assessed by functional magnetic resonance imaging (fMRI) methods that probe local changes in the haemodynamic parameters associated with neuronal activity. Peripheral sensory stimulation of the forepaws leads to fMRI signal in the corresponding somatosensory cortices. After middle cerebral artery (MCA) occlusion, the ipsilateral functionality is lost. The therapeutic objective is to restore function either by sparing the respective area from becoming necrotic or by enhancing plasticity (for more information, see REF. 3).

SEROTONIN SYSTEM
This is an important neurotransmission network involved in aggressive and sexual behaviour, depression, anxiety, the sleep–wake cycle, moods, thermoregulation and other functions.




Figure 3 | Imaging drug pharmacokinetics and pharmacodynamics. a | Representative positron emission tomography (PET) images of human subjects injected with ^{18}F -fluconazole. Images are displayed with a common colour scale ($\mu\text{g mL}^{-1}$ tissue; reprinted with permission from REF. 35 © (1993) American Society for Microbiology). **b** | Axial, sagittal and coronal images of a healthy volunteer injected with the 5-HT₂ ligand ^{18}F -setoperone to image serotonin (5HT₂) receptor occupancy. The top row is before and the bottom row after administration of 40 mg of oral ziprasidone, an antipsychotic agent with high affinity for serotonin and dopamine receptors. Fitting of cortical data was used to determine binding constants and receptor occupancy. Reprinted with permission from REF. 32 © (1996) American Society for Pharmacology and Experimental Therapeutics.

amount of a therapeutic drug that gets into the brain, the minimum effective dose, the duration of action or the binding-site occupancy required to elicit a particular therapeutic or behavioural effect. FIG. 3 shows one example of how imaging of the 5-HT₂ receptors in the human brain can be used to evaluate the effect of an oral dose of the antipsychotic agent ziprasidone within 4 h of administration^{31,32}.

Activatable, or smart, probes are fundamentally different from targeted probes in that they undergo chemical or physicochemical changes on target interaction and, as such, have a built-in amplification strategy. Examples of activatable imaging agents include caged near-infrared fluorochromes (NIRF)², paramagnetic agents that change spin-lattice relaxivity on activation⁵⁵ or superparamagnetic sensors⁵⁶. One example of a protease activatable agent is shown in FIG. 4, in which matrix

metalloproteinase (MMP)2 expression in tumours is visualized using an activatable NIRF agent⁵⁷. Importantly, the efficacy of the model MMP2 inhibitor AG3340 (prinomastat) could be imaged directly after the initiation of drug therapy, and the dose could be tailored accordingly⁵⁷. Activatable NIRF agents have now been developed for several proteases (BOX 1), and the number of available imaging agents is continuously growing. A recently established NIH database — the Molecular Imaging (MOLI) database (see online link) — links the rapidly growing number of imaging agents to the respective targets.

Targeted and activatable imaging probes are key enablers for visualizing drug–target interactions. From a drug developer's point of view, this is certainly a highly attractive feature; however, additional downstream read-outs of drug efficacy are equally important. These surrogate markers might include the activation of individual signalling pathways or markers of metabolic or physiological processes. In an ideal scenario, we would like to have both a direct target-specific read-out and a downstream effector read-out, a result that could be achieved with multichannel imaging⁵⁸. Although the recently reported armamentarium of newer imaging probes is welcome, there remain two methodological hurdles: improving intracellular delivery and developing better amplification methods. Many of the potential molecular imaging targets are located intracellularly. In general, MRI and optical imaging use large reporter moieties, and although such probes can easily target endovascular receptors, interstitial targets or the lysosomal compartment, cytoplasmic or other intracellular locations are more difficult to access. More recently, signalling peptides have been used for intracellular targeting and directing imaging agents^{59,60}. An alternative solution is to use radionuclide-labelled small molecules with improved cellular permeation. Another area of potential improvement concerns the development of more efficient biocompatible amplification strategies (both chemical and biological). These include, for example, multivalency to improve affinity⁶¹, cellular internalization and trapping of imaging ligands^{59,62,63}, MR imaging agents with higher relaxivity and lower detection thresholds, chemical-shift reagents⁶⁴ or fluorescent lifetime agents to reduce background noise⁶⁵.

Optical technologies for molecular imaging

Continued advances in fluorescent probe design, photo-proteins and detection systems are facilitating the application of novel imaging technologies in drug discovery. The adaptation of these tools to the imaging of deep tissues in live animals is now changing the way we visualize molecular processes *in vivo* and, ultimately, in the clinic. The primary enablers have been progress in mathematically modelling photon propagation in tissue, expanding biologically compatible near-infrared (NIR) probes and the introduction of highly sensitive photon-detection technologies. Fluorescence- and bioluminescence-imaging techniques are of particular interest to the drug discovery and development process because of their low cost,

Box 1 | **Some examples of existing imaging targets/probes used for *in vivo* imaging**

- **Proteases:** cathepsin B, cathepsin D, cathepsin K, matrix metalloproteinase (MMP)1, MMP2, MMP7, cytomegalovirus protease, human immunodeficiency virus protease, herpes simplex virus protease, hepatitis C virus protease, caspase-1, caspase-3 and thrombin.
- **Receptors:** somatostatin, bombesin, dopamine D₂ and D₁, serotonin, benzodiazepine, opioid, acetylcholine, adrenoceptor, oestrogen, cholecystokinin, epidermal growth factor receptor, vascular endothelial growth factor receptor (VEGFR), glycoprotein Ib/IIIa, folate, insulin, neurokinin, transforming growth factor, asialoglycoprotein and adenosine 2.
- **Enzymes:** herpes simplex virus thymidine kinase, farnesyl transferase, topoisomerase, cytochrome p450, hexokinase, 3-hydroxyacyl-coenzymeA dehydrogenase (HAD), choline metabolism, citrate metabolism, protein synthesis (amino acids), Akt kinase, β -galactosidase and glutamate carboxipeptidase.
- **Angiogenesis:** E-selectin, $\alpha_v\beta_3$, VEGFR, human vascular cell adhesion molecule 1, endoglin (CD105), thrombin and endostatin.
- **Apoptosis:** annexin-V, caspase-3, PtdS-binding protein, synaptotagmin and tumour necrosis factor-related apoptosis-inducing ligand.
- **Cellular tracking:** CD8, CD4, CD34, neural progenitor cells, stem cells, macrophages, dendritic cells and tumour cells.

versatility and high-throughput capability. There are several other optical techniques being developed, such as NIR spectroscopy^{66,67}, *in vivo* Raman spectroscopy⁶⁸ and multiphoton imaging^{5,69}.

In fluorescence imaging, the energy from an external source of light is absorbed and almost immediately re-emitted at a longer wavelength of lower energy. Fluorescence imaging can be carried out at different resolutions and depth penetrations ranging from micrometres (intravital microscopy⁵) to centimetres (FLUORESCENCE-MEDIATED MOLECULAR TOMOGRAPHY; FMT⁷⁰). One of the key strategies for imaging deeper tissues (that is, more than a few millimetres) has been to use NIR light combined with NIR fluorochromes. Imaging in the NIR region has the advantage of minimizing tissue autofluorescence, which will improve target/background ratios. FLUORESCENCE REFLECTANCE IMAGING (FRI) can be a useful technique when probing superficial structures (<5 mm deep), for example in small animals⁵⁷, during endoscopy^{71,72}, dermatological imaging⁷³, intravascular catheter-based imaging or intraoperative imaging⁷⁴. FMT, the newest optical imaging technology, has recently been shown to three-dimensionally localize and quantify fluorescent probes in deep tissues at high sensitivity. Indeed, it has become possible to image and, importantly, quantitate fluorochrome concentrations at femtomolar levels and at a sub-millimetre spatial resolution of point sources in small animals (FIG. 4, REF. 70). In the near future, FMT techniques are expected to markedly improve in spatial resolution by using higher-density detector systems and advanced photon technologies, such as modulated-intensity light or very-short photon pulses. Clinical FMT imaging applications will ultimately require highly efficient photon-collection systems, but penetration depths of up to 10 cm are theoretically achievable depending on tissue type⁷⁵.

Bioluminescence imaging (BLI) detects luminescence generated by a biochemical reaction during which a photon is released. Firefly luciferin (a benzothiazole) and photinus luciferase are the most commonly used

substrate–enzyme pairs⁷⁶, although several other luciferase–luciferin combinations can be used for image generation^{77,78}. Unlike fluorescence techniques, there is no inherent background signal, which means that BLI is highly sensitive. In contrast to radionuclide imaging techniques, the interpretation of bioluminescence images can be more challenging because of the frequent positional uncertainty of the light-emitting cells. Hence, the primary applications of BLI have so far been either qualitative (“Is luciferase expressed or not?”) or as a semiquantitative imaging tool to follow the same animal under identical conditions. BLI has been used to monitor the efficacy of antibiotic or chemotherapeutic agents, to identify transgenic mice that use luciferase as a reporter gene and to visualize the activation of specific pathways and cellular processes^{2,76,78}. BLI is less likely to be used in human patients, owing to limitations in light penetration and the fact that stable expression of luciferase (or an analogous system) is required to generate a signal.

Impact of imaging on drug discovery

The above examples illustrate the potential of established and emerging imaging technologies in drug discovery and development. When applied properly, imaging methods offer several advantages over other current practices. The use of imaging end points instead of time-consuming dissection and histology can significantly decrease the workload involved in tissue analysis and thereby speed up the evaluation of drug candidates. Imaging might provide biomarkers of a disease process and therefore help to define stratified study groups. As imaging methods are non-invasive, they allow for longitudinal studies in a single animal. This increases the statistical relevance of a study, allows for more clinically relevant study designs and decreases the number of animals required. Imaging will also provide important information on the optimal timing and dosing of drugs. Finally, emerging molecular-imaging tools can provide much earlier surrogate markers of therapy success than is at present possible.

FLUORESCENCE-MEDIATED TOMOGRAPHY

A tomographic reconstruction method developed for *in vivo* imaging of fluorescent probes. Images of deep structures are mathematically reconstructed by solving diffusion equations, under the assumption that photons have been scattered many times.

FLUORESCENCE REFLECTANCE IMAGING

A simple method of image acquisition similar to fluorescence microscopy, except that different optics allow image acquisition of whole animals. Mostly suited for surface tumours or surgically exposed tumours.

In view of these arguments, it is reasonable to assume that imaging might reduce the development time of new drugs and provide tools for faster proof-of-concept testing in clinical studies. The latter is of key interest to the pharmaceutical industry, so why are molecular-imaging biomarkers not already being widely used as end points in clinical trials? First, regulatory agencies have historically relied on end points that require lengthy trials (for example, survival) rather than embracing new read-outs (for example, imaging vascular endothelial growth factor (VEGF)-receptor expression or a downstream target for a VEGF-receptor tyrosine

kinase inhibitor). This is in part due to the fact that many of the newer imaging tools have not yet been sufficiently validated, at least for regulatory purposes. Second, molecular-imaging biomarkers, at present, exist only for a few targets and/or pathways and substantial development is still required. Third, molecular-imaging agents have to undergo lengthy approval processes (often longer than for a therapeutic agent) before their clinical use. Fourth, despite the efforts of various organizations in Europe and the United States (for example, the Society for Noninvasive Imaging in Drug Discovery (SNIDD); see online links), the interactions




Figure 4 | Fluorescence molecular imaging. **a** | Visualization of matrix metalloproteinase (MMP)2 inhibition in a mouse tumour model using an MMP2-activatable, near-infrared (NIR) imaging probe and fluorescence reflecting imaging (FRI). Colour-coded in tumours maps of MMP2 activity are shown merged onto white-light images. **b** | Before treatment, in tumours MMP2 activity is high and decreases markedly within 48 h of an intravenous dose (150 mg kg^{-1}) of the MMP inhibitor prinomastat. Reprinted with permission from REF. 57 © (2001) Macmillan Magazines Ltd. **c** | Quantitative fluorescence-mediated tomography (FMT) imaging⁷⁰ in a mouse model of lung tumour. The animal had been treated with cisplatin and treatment efficacy is shown as binding of NIR fluorochrome-annexin V to apoptotic tumour cells. The bottom row shows reconstructions of the tumour in the three orthogonal planes. Images courtesy of V. Ntziachristos and R. Schulz. **d** | Accuracy of reconstructed fluorochrome concentrations from within tissue phantom.

between the larger imaging and drug development communities have been limited. This is partly due to intellectual property issues but also because of National Institutes of Health priorities in funding disease detection and characterization rather than the development of biomarkers. It is clear that closer and more widespread interactions between these communities would be of mutual interest. Finally, imaging competes with alternative technologies that can provide similar decision-making information; genomic and proteomic sciences detect altered expression levels associated with disease and/or therapy response, and metabonomics potentially yields biomarkers for drug efficacy or for potential safety issues⁷⁹.

Given the broad possibilities, it seems obvious that the pharmaceutical industry must invest in conventional and novel imaging technologies — indeed, we

believe it should drive specific developments for its unique needs. This is particularly true for molecular-imaging applications, for which imaging and therapeutic targets are often the same. A highly specific therapy depends crucially on surveillance strategies (diagnostic kits), which allow for patient selection and close monitoring of the therapy response. Obtaining objective readouts for a patient might also help in tailoring the dosing regimen. The prerequisites for new imaging agents and approaches are clear: the techniques have to be quantitative, reproducible, specific, sensitive, applicable to clinical practice and safe. Developing novel imaging techniques and agents as part of the drug discovery process therefore seems a logical choice. Not only will this speed up drug discovery, but it will also ultimately reduce costs and result in better medicines.

1. Weissleder, R. Scaling down imaging: molecular mapping of cancer in mice. *Nature Rev. Cancer* **2**, 11–18 (2002).
- Review of *in vivo* mouse imaging technologies.**
2. Weissleder, R. & Ntziachristos, V. Shedding light onto live molecular targets. *Nature Med.* **9**, 123–128 (2003).
- This manuscript reviews emerging novel optical *in vivo* imaging technologies.**
3. Rudin, M. *et al.* *In vivo* magnetic resonance methods in pharmaceutical research: current status and perspectives. *NMR Biomed.* **12**, 69–97 (1999).
- Review of MR technologies in drug development.**
4. Beckmann, N., Mueggler, T., Allegrini, P. R., Laurent, D. & Rudin, M. From anatomy to the target: contributions of magnetic resonance imaging to preclinical pharmaceutical research. *Anat. Rec.* **265**, 85–100 (2001).
5. Jain, R. K., Munn, L. L. & Fukumura, D. Dissecting tumour pathophysiology using intravital microscopy. *Nature Rev. Cancer* **2**, 266–276 (2002).
6. Phelps, M. E. Inaugural article: positron emission tomography provides molecular imaging of biological processes. *Proc. Natl Acad. Sci. USA* **97**, 9226–9233 (2000).
- Review of PET imaging applications.**
7. Fischman, A. J., Alpert, N. M. & Rubin, R. H. Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action. *Clin. Pharmacokinet.* **41**, 581–602 (2002).
- Review of the role of PET in the study of drug pharmacokinetics.**
8. Reese, T., Bochen, D., Sauter, A., Beckmann, N. & Rudin, M. Magnetic resonance angiography of the rat cerebrovascular system without the use of contrast agents. *NMR Biomed.* **12**, 189–196 (1999).
9. Villringer, A. *et al.* Dynamic imaging with lanthanide chelates in normal brain: contrast due to magnetic susceptibility effects. *Magn. Reson. Med.* **6**, 164–174 (1988).
10. Roussel, S. A., van Bruggen, N., King, M. D. & Gadian, D. G. Identification of collaterally perfused areas following focal cerebral ischemia in the rat by comparison of gradient echo and diffusion-weighted MRI. *J. Cereb. Blood Flow Metab.* **15**, 578–586 (1995).
11. Moseley, M., Wendland, M. & Kucharczyk, J. Magnetic resonance imaging of diffusion and perfusion. *Top. Magn. Reson. Imag.* **3**, 50–67 (1991).
12. Sauter, A. & Rudin, M. Calcium antagonists reduce the extent of infarction in rat middle cerebral artery occlusion model as determined by quantitative magnetic resonance imaging. *Stroke* **17**, 1228–1234 (1986).
13. Rausch, M., Baumann, D., Neubacher, U. & Rudin, M. *In vivo* visualization of phagocytotic cells in rat brains after transient ischemia by USPIO. *NMR Biomed.* **15**, 278–283 (2002).
14. Sauter, A. *et al.* Recovery of function in cytoprotected cerebral cortex in rat stroke model assessed by functional MRI. *Magn. Reson. Med.* **47**, 759–765 (2002).
15. Cristofanilli, M., Charnsangavej, C. & Hortobagyi, G. N. Angiogenesis modulation in cancer research: novel clinical approaches. *Nature Rev. Drug Discov.* **1**, 415–426 (2002).
16. Tatum, J. L. & Hoffman, J. M. Role of imaging in clinical trials of antiangiogenesis therapy in oncology. *Acad. Radiol.* **7**, 798–799 (2000).
17. Bhujwala, Z. M. *et al.* The physiological environment in cancer vascularization, invasion and metastasis. *Novartis Found. Symp.* **240**, 23–38; discussion 38–45, 152–153 (2001).
18. Lewin, M. *et al.* *In vivo* assessment of vascular endothelial growth factor-induced angiogenesis. *Int. J. Cancer* **83**, 798–802 (1999).
19. Petrovsky, A., Weissleder, W., Shalinsky, D., Hu-Lowe, D. & Bogdanov, A. Non-invasive magnetic resonance imaging (MRI) of vascular parameters affected by VEGF-receptor tyrosine kinase inhibition in a human xenograft model. *Proc. Am. Assoc. Cancer Res.* **43**, 1081 (2002).
20. Peterfy, C. G. Magnetic resonance imaging of rheumatoid arthritis: the evolution of clinical applications through clinical trials. *Semin. Arthritis Rheum.* **30**, 375–396 (2001).
21. McConnell, M. V. *et al.* MRI of rabbit atherosclerosis in response to dietary cholesterol lowering. *Arterioscler. Thromb. Vasc. Biol.* **19**, 1956–1959 (1999).
22. Chinnaiyan, A. M. *et al.* Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. *Proc. Natl Acad. Sci. USA* **97**, 1754–1759 (2000).
23. Jennings, D. *et al.* Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. *Neoplasia* **4**, 255–262 (2002).
24. Evelhoch, J. L. *et al.* Applications of magnetic resonance in model systems: cancer therapeutics. *Neoplasia* **2**, 152–165 (2000).
25. Cherry, S. R. Fundamentals of positron emission tomography and applications in preclinical drug development. *J. Clin. Pharmacol.* **41**, 482–491 (2001).
26. Del Guerra, A. & Belcar, N. Advances in animal PET scanners. *Q. J. Nucl. Med.* **46**, 35–47 (2002).
27. Green, L. A. *et al.* Noninvasive methods for quantitating blood time-activity curves from mouse PET images obtained with fluorine-18-fluorodeoxyglucose. *J. Nucl. Med.* **39**, 729–734 (1998).
28. Chatziannou, A., Tai, Y. C., Doshi, N. & Cherry, S. R. Detector development for microPET II: a 1 microl resolution PET scanner for small animal imaging. *Phys. Med. Biol.* **46**, 2899–2910 (2001).
29. Brady, F. *et al.* Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET. *Curr. Pharm. Des.* **7**, 1863–1892 (2001).
30. Haldin, C., Gulyas, B. & Farde, L. PET studies with carbon-11 radioligands in neuropsychopharmacological drug development. *Curr. Pharm. Des.* **7**, 1907–1929 (2001).
- Review of PET in the development of drugs for mental health disorders.**
31. Fischman, A. J. *et al.* Pharmacokinetics of ¹⁸F-fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography. *Antimicrob. Agents Chemother.* **40**, 659–664 (1996).
32. Fischman, A. J. *et al.* Positron emission tomographic analysis of central 5-hydroxytryptamine₂ receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. *J. Pharmacol. Exp. Ther.* **279**, 939–947 (1996).
33. Aboagye, E. O. *et al.* Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients. *Br. J. Cancer* **86**, 1052–1056 (2002).
34. Gibson, R. E. *et al.* Non-invasive radiotracer imaging as a tool for drug development. *Curr. Pharm. Des.* **6**, 973–989 (2000).
35. Fischman, A. J. *et al.* Pharmacokinetics of ¹⁸F-labeled fluconazole in healthy human subjects by positron emission tomography. *Antimicrob. Agents Chemother.* **37**, 1270–1277 (1993).
36. Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. *Nature Rev. Drug Discov.* **1**, 493–502 (2002).
37. Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. *Science* **295**, 2387–2392 (2002).
38. Warner, R. R. & O'Dorisio T. M. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview. *Semin. Nucl. Med.* **32**, 79–83 (2002).
39. Becker, A. *et al.* Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. *Nature Biotechnol.* **19**, 327–331 (2001).
40. Bugaj, J. E., Achilefu, S., Dorshow, R. B. & Rajagopalan, R. Novel fluorescent contrast agents for optical imaging of *in vivo* tumors based on a receptor-targeted dye-peptide conjugate platform. *J. Biomed. Opt.* **6**, 122–133 (2001).
41. Tung, C. H., Lin, Y., Moon, W. K. & Weissleder, R. A receptor-targeted near-infrared fluorescence probe for *in vivo* tumor imaging. *ChemBiochem* **3**, 784–786 (2002).
42. Weissleder, R. *et al.* *In vivo* magnetic resonance imaging of transgene expression. *Nature Med.* **6**, 351–355 (2000).
43. Hogemann, D., Ntziachristos, V., Josephson, L. & Weissleder, R. High throughput magnetic resonance imaging for evaluating targeted nanoparticle probes. *Bioconjug. Chem.* **13**, 116–121 (2002).
44. Sipkins, D. A. *et al.* Detection of tumor angiogenesis *in vivo* by α V β 3-targeted magnetic resonance imaging. *Nature Med.* **4**, 623–626 (1998).
45. Burns, H. D. *et al.* Positron emission tomography neuroreceptor imaging as a tool in drug discovery, research and development. *Curr. Opin. Chem. Biol.* **3**, 388–394 (1999).
46. Hartvig, P., Bergstrom, M., Antoni, G. & Langstrom, B. Positron emission tomography and brain monoamine neurotransmission — entries for study of drug interactions. *Curr. Pharm. Des.* **8**, 1417–1434 (2002).
47. Fowler, J. S. *et al.* Positron emission tomography studies of dopamine-enhancing drugs. *J. Clin. Pharmacol. (Suppl.)* **13**–16 (1999).
48. Hietala, J. Ligand-receptor interactions as studied by PET: implications for drug development. *Ann. Med.* **31**, 438–443 (1999).
49. Laakso, A. & Hietala, J. PET studies of brain monoamine transporters. *Curr. Pharm. Des.* **6**, 1611–1623 (2000).
50. Passchier, J. & van Vaarde, A. Visualisation of serotonin-1A (5-HT_{1A}) receptors in the central nervous system. *Eur. J. Nucl. Med.* **28**, 113–129 (2001).
51. Pilowsky, L. S. Probing targets for antipsychotic drug action with PET and SPET receptor imaging. *Nucl. Med. Commun.* **22**, 829–833 (2001).
52. Volkow, N. D., Ding, Y. S., Fowler, J. S. & Gatley, S. J. Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia. *Biol. Psychiatry* **49**, 211–220 (2001).
53. Waarde, A. Measuring receptor occupancy with PET. *Curr. Pharm. Des.* **6**, 1593–1610 (2000).

54. Martinez, D. *et al.* Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: a dose-occupancy study with ^{11}C WAY 100635 and positron emission tomography in humans. *Neuropsychopharmacology* **24**, 209–229 (2001).
55. Louie, A. Y. *et al.* *In vivo* visualization of gene expression using magnetic resonance imaging. *Nature Biotechnol.* **18**, 321–325 (2000).
56. Perez, J. M., Josephson, L., O'Loughlin, T., Hogemann, D. & Weissleder, R. Magnetic relaxation switches capable of sensing molecular interactions. *Nature Biotechnol.* **20**, 816–820 (2002).
57. Bremer, C., Tung, C. H. & Weissleder, R. *In vivo* molecular target assessment of matrix metalloproteinase inhibition. *Nature Med.* **7**, 743–748 (2001).
58. Mahmood, U., Tung, C. H., Tang, Y. & Weissleder, R. Feasibility of *in vivo* multichannel optical imaging of gene expression: experimental study in mice. *Radiology* **224**, 446–451 (2002).
59. Lewin, M. *et al.* Tat peptide-derivatized magnetic nanoparticles allow *in vivo* tracking and recovery of progenitor cells. *Nature Biotechnol.* **18**, 410–414 (2000).
60. Sharma, V., Luker, G. D. & Pivnicka-Worms, D. Molecular imaging of gene expression and protein function *in vivo* with PET and SPECT. *J. Magn. Reson. Imaging* **16**, 336–351 (2002).
61. Zhao, M., Kircher, M. F., Josephson, L. & Weissleder, R. Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. *Bioconjug. Chem.* **13**, 840–844 (2002).
62. Tjuvajev, J. G. *et al.* Imaging the expression of transfected genes *in vivo*. *Cancer Res.* **55**, 6126–6132 (1995).
63. Gambhir, S. S. *et al.* Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. *Proc. Natl Acad. Sci. USA* **96**, 2333–2338 (1999).
64. Li, X., Zhang, S., Zhao, P., Kovacs, Z. & Sherry, A. D. Synthesis and NMR studies of new DOTA-like lanthanide(III) complexes containing a hydrophobic substituent on one phosphonate side arm. *Inorg. Chem.* **40**, 6572–6579 (2001).
65. Bornhop, D. J. *et al.* Fluorescent tissue site-selective lanthanide chelate, Tb-PCTMB for enhanced imaging of cancer. *Anal. Chem.* **71**, 2607–2615 (1999).
66. Tromberg, B. J. *et al.* Non-invasive *in vivo* characterization of breast tumors using photon migration spectroscopy. *Neoplasia* **2**, 26–40 (2000).
67. Chance, B. Near-infrared (NIR) optical spectroscopy characterizes breast tissue hormonal and age status. *Acad. Radiol.* **8**, 209–210 (2001).
68. Hanlon, E. B. *et al.* Prospects for *in vivo* Raman spectroscopy. *Phys. Med. Biol.* **45**, R1–R59 (2000).
69. Brown, E. B. *et al.* *In vivo* measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. *Nature Med.* **7**, 864–868 (2001).
70. Ntziachristos, V., Tung, C. H., Bremer, C. & Weissleder, R. Fluorescence molecular tomography resolves protease activity *in vivo*. *Nature Med.* **8**, 757–760 (2002).
71. Marten, K. *et al.* Detection of dysplastic intestinal adenomas using enzyme-sensing molecular beacons in mice. *Gastroenterology* **122**, 406–414 (2002).
72. Ito, S. *et al.* Detection of human gastric cancer in resected specimens using a novel infrared fluorescent anti-human carcinoembryonic antigen antibody with an infrared fluorescence endoscope *in vitro*. *Endoscopy* **33**, 849–853 (2001).
73. Zonios, G., Bykowski, J. & Kollias, N. Skin melanin, hemoglobin, and light scattering properties can be quantitatively assessed *in vivo* using diffuse reflectance spectroscopy. *J. Invest. Dermatol.* **117**, 1452–1457 (2001).
74. Kuroiwa, T., Kajimoto, Y. & Ohta, T. Development and clinical application of near-infrared surgical microscope: preliminary report. *Minim. Invasive. Neurosurg.* **44**, 240–242 (2001).
75. Ntziachristos, V., Ripoll, J. & Weissleder, R. Would near-infrared fluorescence signals propagate through large human organs for clinical studies? *Opt. Lett.* **27**, 333–335 (2002).
76. Contag, C. H. *et al.* Visualizing gene expression in living mammals using a bioluminescent reporter. *Photochemistry & Photobiology* **66**, 523–531 (1997).
77. Hastings, J. W. Chemistries and colors of bioluminescent reactions: a review. *Gene* **173**, 5–11 (1996).
78. Bhaumik, S. & Gambhir, S. S. Optical imaging of Renilla luciferase reporter gene expression in living mice. *Proc. Natl Acad. Sci. USA* **99**, 377–382 (2002).
79. Nicholson, J. K., Connelly, J., Lindon, J. C. & Holmes, E. Metabonomics: a platform for studying drug toxicity and gene function. *Nature Rev. Drug Discov.* **1**, 153–161 (2002).

Online links

FURTHER INFORMATION

Academy of Molecular Imaging (AMI):
<http://www.ami-imaging.org>

Encyclopedia of Life Sciences: <http://www.els.net>
 computer tomography | magnetic resonance imaging

Molecular Imaging (MOLI) Database: <http://207.238.28.146>
Society for Magnetic Resonance in Medicine (ISMRM):
<http://www.ismrm.org>

Society for Molecular Imaging (SMI):
<http://www.molecularimaging.org>

Society for Non-invasive Imaging in Drug Discovery (SNIDD):
<http://www.snidd.org>

Society of Nuclear Medicine (SNM): <http://www.snm.org>
Access to this interactive links box is free online.